Private Innovation in the Public Interest

101: Colleen Cunningham. Guardrails + Incentives - Excessive Competition = Innovation

25 min · 23 de abr de 2026
Portada del episodio 101: Colleen Cunningham. Guardrails + Incentives - Excessive Competition = Innovation

Descripción

Professor Colleen Cunningham studies why and how companies accomplish innovations that benefit the public, such as in pharmaceuticals and alternative energy.  She sees a role for government in clarifying the guardrails on what’s allowed, but that’s not enough to get great outcomes.  It’s also important for government – and for civil society at a broad level – to make sure that the incentives reward innovators given the risks they must endure.  Yet even that’s not enough.  It’s also important to make sure that the right amount of competitive behavior arises.   You want some secrecy as innovators protect against imitation, but enough knowledge-sharing for insights to accumulated.   The formula:  Guardrails + incentives – excessive competition.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Private Innovation in the Public Interest!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

110 episodios

episode 110: Brent Goldfarb. Great scientists think big, think long-term, and have integrity artwork

110: Brent Goldfarb. Great scientists think big, think long-term, and have integrity

Professor Brent Goldfarb studies big ideas, arguing that short-term investor pressures can cause firms to innovate less than they might otherwise.   Brent also studies how well-intentioned corporate innovators may pull the plug on their work once they achieve results that are good enough to pass muster – even when breakthroughs are just around the corner.  With training in both economics and computerscience, he brings a long view – an historian’s sensibility – to trajectories of scientific commercialization through corporate action.   Despite all the challenges, Brent remains excited and optimistic that science can deliver the insights we need forprosperity in the face of AI.

25 de jun de 202630 min